Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis
- 28 March 2023
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 260 (2) , 112-123
Abstract
Multiple myeloma (MM) remains an incurable haematological malignancy despite substantial advances in therapy. Hypoxic bone marrow induces metabolic rewiring in MM cells contributing to survival and drug resistance. Therefore, targeting metabolic pathways may offer an alternative treatment option. In this study, we repurpose two FDA‐approved drugs, syrosingopine and metformin. Syrosingopine was used as a dual inhibitor of monocarboxylate transporter 1 and 4 (MCT1/4) and metformin as an inhibitor for oxidative phosphorylation (OXPHOS). Anti‐tumour effects were evaluated for single agents and in combination therapy. Survival and expression data for MCT1/MCT4 were obtained from the Total Therapy 2, Mulligan, and Multiple Myeloma Research Foundation cohorts. Cell death, viability, and proliferation were measured using Annexin V/7‐AAD, CellTiterGlo, and BrdU, respectively. Metabolic effects were assessed using Seahorse Glycolytic Rate assays and LactateGlo assays. Differential protein expression was determined using western blotting, and the SUnSET method was implemented to quantify protein synthesis. Finally, the syngeneic 5T33MMvv model was used for in vivo analysis. High‐level expression of MCT1 and MCT4 both correlated with a significantly lower overall survival of patients. Lactate production as well as MCT1/MCT4 expression were significantly upregulated in hypoxia, confirming the Warburg effect in MM. Dual inhibition of MCT1/4 with syrosingopine resulted in intracellular lactate accumulation and reduced cell viability and proliferation. However, only at higher doses (>10 μm) was syrosingopine able to induce cell death. By contrast, combination treatment of syrosingopine with metformin was highly cytotoxic for MM cell lines and primary patient samples and resulted in a suppression of both glycolysis and OXPHOS. Moreover, pathway analysis revealed an upregulation of the energy sensor p‐AMPKα and more downstream a reduction in protein synthesis. Finally, the combination treatment resulted in a significant reduction in tumour burden in vivo. This study proposes an alternative combination treatment for MM and provides insight into intracellular effects. © 2023 The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (1159622N, 12I0921N, I001420N)
- Kom op tegen Kanker
- Vrije Universiteit Brussel (SRP48)
This publication has 36 references indexed in Scilit:
- The SLC16 gene family – Structure, role and regulation in health and diseaseMolecular Aspects of Medicine, 2013
- Adaptation to Survival in Germinal Center Is the Initial Step in Onset of Indolent Stage of Multiple MyelomaMolecular Pharmaceutics, 2011
- CD147 subunit of lactate/H+symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumorsProceedings of the National Academy of Sciences, 2011
- The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcomeBlood, 2010
- IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanismsBlood, 2010
- Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-AminoadenosineJournal of Biological Chemistry, 2009
- SUnSET, a nonradioactive method to monitor protein synthesisNature Methods, 2009
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomibBlood, 2006
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myelomaOncogene, 2001